



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

QUEENSLAND FACILITY FOR ADVANCED BIOINFORMATICS (QFAB) BECOMES A GENEGO CENTER OF EXCELLENCE FOR THE ASIA PACIFIC REGION

St. Joseph, MI. February 2nd, 2009 –GeneGo, Inc., the leading systems biology tools company, announced today that QFAB has licensed MetaCore and entered a co marketing agreement with GeneGo for the Asia Pacific region. QFAB will have GeneGo certified experts on staff to run training classes in the region and support the local research community. QFAB will make MetaCore pathway tools, software and manually curated databases accessible to Australian and New Zealand academics as part of its delivery of tailored bioinformatics solutions to life science researchers in the region.

Jeremy Barker, QFAB’s Chief Executive Officer said, “We are currently using MetaCore for an in-house project and have seen the power that it provides in a systems biology framework. In partnering with GeneGo we aim to help researchers in our part of the world realize the benefits that can come from using this software.”

“We are very excited about this relationship as we will work together to open up and support Australia, New Zealand and beyond,” said Julie Bryant, GeneGo’s VP of Business development. “We will be jointly supporting a lot of marketing and research activities in the region as there is a lot of exciting and novel research we would like to be involved in.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.2™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.